THRB and metabolic dysfunction-associated steatotic liver disease: Thus, the high prevalence of hypothyroidism, the fact that levothyroxine is a widely available and affordable treatment and recent data providing evidence that THR-b agonists are effective in the treatment of dyslipidemia and NAFLD, all contribute to the growing interest in this association.